Colorectal

10-Year KEYNOTE-016: Pembrolizumab Durable in MSI-H/dMMR Tumors
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
Advertisement
Advertisement